Uridine diphosphate derivatives, compositions and methods for treating neurodegenerative disorders

Abstract

This disclosure relates to uridine di phosphate (UDP) derivatives, compositions comprising therapeutically effective amounts of those UDP derivatives and methods of using those derivatives or compositions in treating disorders that are responsive to ligands, such as agonists, of P 2 Y 6 receptor, e.g., neuronal disorders, including neurodegenerative disorders (e.g., Alzheimer's disease) and traumatic CNS injury, as well as pain.

1 - 30 . (canceled) 
     
     
         31 . A compound of formula I: 
       
         
           
           
               
               
           
         
         or a salt thereof, wherein: 
         A is an optionally substituted 5- or 6-membered aromatic ring having up to 2 heteroatoms selected from N, O and S, wherein the aromatic ring is independently and optionally substituted with one or more R 7 ; 
         X is independently selected from —O—, —S—, —N(R 5 )— and a (C1-C3)-aliphatic group independently and optionally substituted with one or more R 4 ; 
         Y is a bond or a (C1-C5)-aliphatic group independently and optionally substituted with one or more R 4 ; 
         Z and W are each independently selected from ═O, ═S, ═N(R 5 ), or ═NOR 5 ; 
         R 1  is selected from:
 —H, halogen, —OR 5 , —CN, —CF 3 , —OCF 3  or a (C1-C6)-aliphatic group optionally substituted with one or more R 7 ; 
 
         R 2  and R 3  are each independently selected from —OR 5 , —SR 5 , —NR 5 R 6 , —OC(O)R 5 , —OC(O)NR 5 R 6 , and —OC(O)OR 5 ; 
         each occurrence of R 4  is independently selected from:
 halogen, —OR 5 , —NO 2 , —CN, —CF 3 , —OCF 3 , —R 5 , 1,2-methylenedioxy, 1,2-ethylenedioxy, —N(R 5 ) 2 , —SR 5 , —SOR 5 , —SO 2 R 5 , —SO 2 N(R 5 ) 2 , —SO 3 R 5 , —C(O)R 5 , —C(O)C(O)R 5 , —C(O)CH 2 C(O)R 5 , —C(S)R 5 , —C(S)OR 5 , —C(O)OR 5 , —C(O)C(O)OR 5 , —C(O)C(O)N(R 5 ) 2 , —OC(O)R 5 , —C(O)N(R 5 ) 2 , —OC(O)N(R 5 ) 2 , —C(S)N(R 5 ) 2 , —(CH 2 ) 0-2 NHC(O)R 5 , —N(R 5 )N(R 5 )COR 5 , —N(R 5 )N(R 5 )C(O)OR 5 , —N(R 5 )N(R 5 )CON(R 5 ) 2 , —N(R 5 )SO 2 R 5 , —N(R 5 )SO 2 N(R 5 ) 2 , —N(R 5 )C(O)OR 5 , —N(R 5 )C(O)R 5 , —N(R 5 )C(S)R 5 , —N(R 5 )C(O)N(R 5 ) 2 , —N(R 5 )C(S)N(R 5 ) 2 , —N(COR 5 )COR 5 , —N(OR 5 )R 5 , —C(═NH)N(R 5 ) 2 , —C(O)N(OR 5 )R 5 , —C(═NOR 5 )R 5 , —OP(O)(OR 5 ) 2 , —P(O)(R 5 ) 2 , —P(O)(OR 5 ) 2 , or —P(O)(H)(OR 5 ); 
 
         each occurrence of R 5  is independently selected from:
 H—, 
 (C1-C12)-aliphatic-, 
 (C3-C10)-cycloalkyl- or -cycloalkenyl-, 
 [(C3-C10)-cycloalkyl or -cycloalkenyl]-(C1-C12)-aliphatic-, 
 (C6-C10)-aryl-, 
 (C6-C10)-aryl-(C1-C12)aliphatic-, 
 (C3-C10)-heterocyclyl-, 
 (C6-C10)-heterocyclyl-(C1-C12)aliphatic-, 
 (C5-C10)-heteroaryl-, or 
 (C5-C10)-heteroaryl-(C1-C12)-aliphatic-; 
 wherein two R 5  groups bound to the same atom optionally form a 3- to 10-membered aromatic or non-aromatic ring having up to 3 heteroatoms independently selected from N, O, S, SO, and SO 2 , 
 wherein said ring is optionally fused to a (C6-C10)aryl, (C5-C10)heteroaryl, (C3-C10)cycloalkyl, or a (C3-C10)heterocyclyl; and 
 wherein each R 5  group is independently and optionally substituted with one or more R 7 ; 
 
         R 6  is selected from:
 —R 5 , —C(O)R 5 , —C(O)OR 5 , —C(O)N(R 5 ) 2  and —S(O) 2 R 5 ; 
 
         each occurrence of R 7  is independently selected from:
 halogen, —OR 8 , —NO 2 , —CN, —CF 3 , —OCF 3 , —R 8 , oxo, thioxo, 1,2-methylenedioxy, 1,2-ethylenedioxy, —N(R 8 ) 2 , —SR 8 , —SOR B , —SO 2 R 8 , —SO 2 N(R 8 ) 2 , —SO 3 R 8 , —C(O)R 8 , —C(O)C(O)R 8 , —C(O)CH 2 C(O)R 8 , —C(S)R 8 , —C(S)OR 8 , —C(O)OR 8 , —C(O)C(O)OR 8 , —C(O)C(O)N(R 8 ) 2 , —OC(O)R 8 , —C(O)N(R 8 ) 2 , —OC(O)N(R 8 ) 2 , —C(S)N(R 8 ) 2 , —(CH 2 ) 0-2 NHC(O)R 8 , —N(R 8 )N(R 8 )COR 8 , —N(R 8 )N(R 8 )C(O)OR 8 , —N(R 8 )N(R 8 )CON(R 8 ) 2 , —N(R 8 )SO 2 R 8 , —N(R 8 )SO 2 N(R 8 ) 2 , —N(R 8 )C(O)OR 8 , —N(R 8 )C(O)R 8 , —N(R 8 )C(S)R 8 , —N(R 8 )C(O)N(R 8 ) 2 , —N(R 8 )C(S)N(R 8 ) 2 , —N(COR 8 )COR 8 , —N(OR 8 )R 8 , —C(═NH)N(R 8 ) 2 , —C(O)N(OR 8 )R 8 , —C(═NOR 8 )R 8 , —OP(O)(OR 8 ) 2 , —P(O)(R 8 ) 2 , —P(O)(OR 8 ) 2 , or —P(O)(H)(OR 8 ); 
 
         each occurrence of R 8  is independently:
 H— or (C1-C6)-aliphatic-. 
 
       
     
     
         32 . The compound of  claim 31 , wherein A is selected from the group consisting of: 
       
         
           
           
               
               
           
         
         wherein A is optionally further substituted with one or more R 7 . 
       
     
     
         33 . The compound of  claim 31 , wherein A is 
       
         
           
           
               
               
           
         
       
       wherein A is optionally further substituted with one or more R 7 . 
     
     
         34 . The compound of  claim 31 , wherein X is —O—. 
     
     
         35 . The compound of  claim 31 , wherein R 1  is —H, bromine, iodine, methyl, ethyl or —CF 3 . 
     
     
         36 . The compound of  claim 31 , wherein Z is ═O or ═S. 
     
     
         37 . The compound of  claim 31 , wherein W is ═O or ═S. 
     
     
         38 . The compound of  claim 31 , wherein Y is a C1-aliphatic group optionally substituted with one or more R 4 . 
     
     
         39 . The compound of  claim 31 , wherein Y is a C2-aliphatic group optionally substituted with one or more R 4 . 
     
     
         40 . The compound of  claim 39 , wherein each occurrence of R 4  is independently selected from halogen. 
     
     
         41 . The compound of  claim 39 , wherein each occurrence of R 4  is independently a (C1-C3)-aliphatic group. 
     
     
         42 . The compound of  claim 31 , wherein R 2  is —OR 5 . 
     
     
         43 . The compound of  claim 31 , wherein R 3  is —OR 5 . 
     
     
         44 . The compound of  claim 31 , wherein said compound is selected from: 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof. 
       
     
     
         45 . A pharmaceutical composition, comprising a compound according to  claim 31  and an acceptable carrier, adjuvant or vehicle.